Cutaneous Dermatomyositis

Dazukibart, a type I interferon inhibitor, reduced dermatomyositis disease severity while maintaining a well-tolerated safety profile among patients, according to a study.

Apremilast may be an efficacious and safe treatment option for patients with recalcitrant cutaneous dermatomyositis, according to a study.

A thorough physical exam and attention to a patient’s medical history are integral to differentiating dermatomyositis from cutaneous dermatomyositis with similar features, according to a presenter here.